INTRODUCTION
============

Ovarian cancer (OC) and endometrial cancer (EC) account for almost 40% of deaths from gynecologic cancers and share some similarities.^[@B1]^ Both develop from Müllerian epithelium and either show a more indolent growth pattern with a good prognosis (type I) or an aggressive phenotype with a poor prognosis (type II).^[@B2]^

Of all OCs, approximately 75% are type II, classified as high-grade serous cancers (HGSCs). HGSCs show frequent mutations in the *TP53* gene (\> 90%), early transperitoneal dissemination, and a poor prognosis with a 5-year survival rate of 10% to 30%.^[@B3]^ Over the last decade, the origin of OC has been reconsidered. The weight of current evidence suggests serous tubal intraepithelial carcinomas (STICs) to be precursor lesions of HGSC. There is growing evidence that the lag time from STIC to clinically overt HGSC is approximately 5 years.^[@B4]^ Recent studies demonstrated that intraluminal shedding of tumor cells from OCs and STICs occurred frequently.^[@B5]^

Of all ECs, approximately 10% are type II. Histologically, these tumors are classified as serous, clear cell, or poorly to undifferentiated endometrioid. Because of early transperitoneal dissemination and lymph node metastasis, prognosis of type II EC is poor, accounting for approximately 40% of EC mortality and with a 5-year survival rate of 50% to 60%.^[@B6]^

In addition, for type II EC, a lesion that seems to play an important role in carcinogenesis has been identified, called endometrial intraepithelial carcinoma. Similar to serous EC, endometrial intraepithelial carcinoma is associated with mutations and an abnormal accumulation of the TP53 protein.^[@B7]^

Late diagnosis is a large contributor to the poor prognosis of these cancers. Serum CA-125 measurement and transvaginal ultrasound are the most commonly used tests for diagnosis. Specificity and sensitivity of both are low, making them ineffective for screening and early or differential diagnosis.^[@B8],[@B9]^ In the United States, 5% to 10% of women undergo surgery for a suspected ovarian neoplasm at least once during their life,^[@B10]^ and the majority of these procedures reveal only benign diseases.^[@B11]--[@B14]^ In part, this is a result of difficulties in discrimination before surgery and why only 30% to 50% of women with OC receive optimum treatment by a gynecologic oncologist.^[@B15],[@B16]^ Studies have shown that surgical treatment in specialized centers results in a better survival, proving the benefit of a method able to discriminate between a benign or malignant lesion.^[@B17]^ Familial or inherited syndromes account for 10% to 15% of HGSCs.^[@B18]^ *BRCA1* and *BRCA2* mutation carriers have a 54% and 23% estimated lifetime risk of developing HGSC, respectively.^[@B19]^ Even in this high-risk group, screening with serum CA-125 measurement and transvaginal ultrasound was not able to improve clinical outcomes.^[@B8]^ At present, risk-reducing salpingo-oophorectomy (RRSO) is the only effective approach to reduce the risk of HGSC in these women.^[@B20],[@B21]^ Thus, there is a clear and unmet clinical need for earlier detection of HGSC and type II EC.

A study published by Kinde et al^[@B22]^ made use of the so-called liquid Pap, which is routinely used for human papillomavirus detection, and showed that cells of gynecologic Müllerian duct cancers can be present in the uterine cervix. Massively parallel sequencing for tumor-specific mutations was performed on DNA from liquid Pap smear specimens. This technique was successfully applied to 24 (100%) of 24 patients with EC. In patients with OC, the sensitivity was less, with mutations identified in nine (41%) of 22 patients.

In this article, we describe a new method based on recent insights concerning the pathogenesis and characteristics of Müllerian tumors. The ovarian surface, fallopian tube, and uterine cavity form a communicating space. Peristaltic waves allow the fallopian tube to function as a conduit, possibly transporting exfoliated cells from HGSCs or STICs into the uterine cavity. We want to address whether cells from Müllerian duct cancers can be collected with a lavage of the uterine cavity. This lavage concept could improve both the earlier detection of type II Müllerian duct cancers and the differential diagnosis of adnexal masses.

PATIENTS AND METHODS
====================

Patient Samples
---------------

Samples were collected in accordance with the institutional review boards of the Medical University of Vienna (EK\#1148_2011, EK\#1766_2013), the Catholic University Leuven (B322201214864/S54406), the Kliniken Essen-Mitte (LÄNR_2013456), and the Charité Medical University of Berlin (EA2/025/14). Informed consent was obtained from each participant. Patients with the following diagnoses were included ([Table 1](#T1){ref-type="table"}): OC (n = 30), EC (n = 5), benign gynecologic diseases (n = 27), and other malignancies with involvement of gynecologic organs (n = 7). To increase the number of patients with malignant diagnosis, three patients (patients 196, 197, and 198) were randomly selected from the prospective running Lavage of the Uterine Cavity for the Diagnosis of Ovarian and Tubal Carcinoma and Their Premalignant Changes (LUDOC) study (ClinicalTrials.gov identifier: NCT02387645). To prove that exfoliated cells may be present even in a clinically occult stage of disease, one patient (patient 205) from the prospective running Lavage of the Uterine Cavity for the Diagnosis of Serous Tubal Intraepithelial Carcinoma (LUSTIC) study (ClinicalTrials.gov identifier: NCT02039388) was included. In all 73 patients, lavage specimens were taken for subsequent mutation analysis. Eight patients were excluded from final analysis for one of the following reasons ([Table 1](#T1){ref-type="table"}): two or more malignant tumors were present, tubal ligation was performed previously, patients were suspected of harboring a germline mutation, or primary tumor tissue was available but did not harbor any of the tested mutations.

###### 

Characteristics of the Study Cohort and Index Mutation Assessed in Primary Tumor Tissues and Lavage Specimens by NGS and Singleplex Approaches
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  Patient No.                            Age (years)   Type of Disease   Histology                                                                                        FIGO Stage   Grade   Mutations in Primary Tumor                                   Mutations in Lavage Specimen                                       Notes
  -------------------------------------- ------------- ----------------- ------------------------------------------------------------------------------------------------ ------------ ------- ------------------------------------------------------------ ------------------------------------------------------------------ -----------------------------------------
  154                                    55            OC                Endometrioid                                                                                     IA           G1      *FGFR2* p.K659E, c.1975T\>C                                  *FGFR2* p.K659E, c.1975T\>C (1)                                    
  155                                    45            OC                Serous                                                                                           IC           G1      *PIK3CA* p.H1047R, c.3140A\>G                                *PIK3CA* p.H1047R, c.3140A\>G (3)                                  
  152                                    50            OC                Serous                                                                                           IIC          G3      *TP53* p.R248Q, c.743G\>A                                    *TP53* p.R248Q, c.743G\>A (1)                                      
  140                                    44            OC                Serous                                                                                           IIIA         G3      *TP53* p.H168R, c.503A\>G                                    *TP53* p.H168R, c.503A\>G (3)                                      
  149                                    57            OC                Serous                                                                                           IIIA         G3      *TP53* p.V272E, c.815T\>A                                    *TP53* p.V272E, c.815T\>A (3)                                      
  148                                    71            OC                Serous                                                                                           IIIB         G3      *TP53* p.V216M, c.646G\>A                                    *TP53* p.V216M, c.646G\>A (1)                                      
  205                                    42            OC                Serous                                                                                           IIIB         G2      *TP53* p.V217*fs*, c.650delT                                 *TP53* p.V217*fs*, c.650delT (1)                                   
  143                                    52            OC                Serous                                                                                           IIIC         G3      *TP53* p.C135Y, c.404G\>A                                    *TP53* p.L194R, c.581T\>G (3)                                      
  158                                    49            OC                Serous                                                                                           IIIC         G3      *TP53* p.G245V, c.734G\>T                                    *TP53* p.G245V, c.734G\>T (3)                                      
  130                                    72            OC                Serous                                                                                           IIIC         G2      *PPP2R1A* p.W257C, c.771G\>T                                 *PPP2R1A* p.W257C, c.771G\>T (1)                                   
  132                                    64            OC                Serous                                                                                           IIIC         G2      NA                                                           *TP53* p.M237I, c.711G\>C (1)                                      
  139                                    70            OC                Serous                                                                                           IIIC         G3      *TP53* p.H193P, c.578A\>C                                    *TP53* p.H193P, c.578A\>C (1)                                      
  144                                    43            OC                Serous                                                                                           IIIC         G3      *TP53* p.G245S, c.733G\>A                                    *KRAS* p.G12C, c.34G\>T (1)                                        
  160                                    35            OC                Serous                                                                                           IIIC         G3      *TP53* p.T170 (in-frame deletion), c.508_510delACG           *TP53* p.T170 (in-frame deletion), c.508_510delACG (2)             
  168                                    58            OC                Serous                                                                                           IIIC         G3      *TP53* p.R273H, c.818G\>A                                    *TP53* p.R273H, c.818G\>A (1)                                      
  197                                    73            OC                Serous                                                                                           IIIC         G3      NA                                                           *KRAS* p.G12A, c.35G\>C (1)                                        
  137                                    61            OC                Serous                                                                                           IIIC         G3      *TP53* p.H179R, c.536A\>G                                    *TP53* p.H179R, c.536A\>G (1)                                      
  194                                    49            OC                Malignant mixed Müllerian tumor                                                                  IIIC         G3      NA                                                           *NRAS* p.Q61R, c.182A\>G (1)                                       
  196                                    59            OC                Malignant mixed Müllerian tumor                                                                  IIIA1(i)     G3      NA                                                           *PIK3CA* p.T1025N, c.3074C\>A (1)                                  
  131                                    55            OC                Endometrioid, partly serous                                                                      IIIC         G2      *KRAS* p.G13D, c.38G\>A                                      *KRAS* p.G13D, c.38G\>A (1)                                        
  147                                    60            OC                Endometrioid                                                                                     IIIC         G3      *KRAS* p.G12D, c.35G\>A                                      *KRAS* p.G12D, c.35G\>A (1)                                        
  204                                    61            OC                Clear cell                                                                                       IIIC         G3      NA                                                           *TP53* p.A159I, c.475_476GC\>AT (1)                                
  198                                    59            OC                Serous                                                                                           IVB          G3      NA                                                           *PIK3CA* p.M1004V, c.3010A\>G (1)                                  
  172                                    55            OC                Serous                                                                                           IV           G3      NA                                                           *TP53* p.G262V, c.785G\>T (1)                                      
  133                                    31            OC LMP            Serous low malignant potential                                                                                        NA                                                           *AKT1* p.E17K, c.49G\>A (1)                                        
  161                                    52            OC meta           Signet ring carcinoma, spread in ovaries                                                                              *TP53* p.R282W, c.844C\>T                                    *TP53* p.R282W, c.844C\>T (1)                                      
  164                                    72            UC                Uterine carcinosarcoma                                                                           IIIC         G3      NA                                                           *PTEN* p.L193fs, c.578delT (1)                                     
  199                                    73            EC                EC                                                                                               IA           G2      *PTEN* p.R130[\*](#TF1-1){ref-type="table-fn"}, c.388C\>T    *PTEN* p.R130[\*](#TF1-1){ref-type="table-fn"}, c.388C\>T (1)      
  200                                    70            EC                EC                                                                                               IA           G2      *PIK3CA* p.H1047Y, c.3139C\>T                                *PIK3CA* p.H1047Y, c.3139C\>T (1)                                  
  201                                    70            EC                EC                                                                                               IA           G2      *APC* p.Q1469[\*](#TF1-1){ref-type="table-fn"}, c.4405C\>T   *APC* p.Q1469[\*](#TF1-1){ref-type="table-fn"}, c.4405C\>T (1)     
  202                                    63            EC                EC                                                                                               IA           G1      NA                                                           *PTEN* p.Y315[\*](#TF1-1){ref-type="table-fn"}, c.945T\>A (1)      
  203                                    55            EC                EC                                                                                               IA           G1      NA                                                           *CTNNB1* p.S37F, c.110C\>T (1)                                     
  165                                    61            B                 Fibroma                                                                                                               NA                                                           *FBXW7* p.R505S, c.1513C\>A (1)                                    
  175                                    50            B                 Ovarian cyst, teratoma                                                                                                ---                                                          *KRAS* p.G12V, c.35G\>T (1)                                        
  177                                    31            B                 Secondary infertility                                                                                                 NA                                                           *KRAS* p.G12C, c.34G\>T (1)                                        
  178                                    46            B                 Uterus myomatosus, ovarian cyst                                                                                       ---                                                          *KRAS* p.G12C, c.34G\>T (1)                                        
  181                                    43            B                 Secondary infertility, polyp of the cervix mucosa                                                                     NA                                                           *KRAS* p.G12V, c.35G\>T (1)                                        
  184                                    78            B                 Ovarian cyst                                                                                                          ---                                                          *KRAS* p.G12V, c.35G\>T (1)                                        
  190                                    58            B                 Teratoma                                                                                                              ---                                                          *PIK3R1* p.R348[\*](#TF1-1){ref-type="table-fn"}, c.1042C\>T (1)   
  193                                    54            B                 Inclusion cysts                                                                                                       ---                                                          *KRAS* p.G12D, c.35G\>A (1)                                        
  146[\*](#TF1-1){ref-type="table-fn"}   39            BC                Breast cancer, uterine leiomyoma                                                                                      NA                                                           *TP53* p.C242F, c.725G\>T (1)                                      Germline mutation
  162[\*](#TF1-1){ref-type="table-fn"}   77            B                 Ovarian serous cystadenoma (previous leukemia, signet ring carcinoma, squamous cell carcinoma)                        NA                                                           *TP53* p.N239D, c.715A\>G (1)                                      Two or more malignant tumors
  129                                    82            OC                Serous                                                                                           IIIC         G2      *TP53* c.920-1G\>A, g.7576927C\>T (splice site)              ---                                                                
  150                                    51            OC                Serous                                                                                           IIIC         G3      *TP53* p.C176Y, c.527G\>A                                    ---                                                                
  163                                    67            OC                Serous                                                                                           IIIC         G3      *TP53* p.C238R, c.712T\>C                                    ---                                                                
  195                                    69            OC                Serous                                                                                           IIIC         G2      NA                                                           ---                                                                
  166                                    77            OC                Serous                                                                                           IV           G3      NA                                                           ---                                                                
  174                                    69            OC                Serous                                                                                           IV           G3      *TP53* p.R342[\*](#TF1-1){ref-type="table-fn"}, c.1024C\>T   ---                                                                
  145                                    52            B                 Cervix mucous polyp                                                                                                   ---                                                          ---                                                                
  136                                    49            B                 Follicle cyst                                                                                                         NA                                                           ---                                                                
  138                                    47            B                 Uterus myomatosus                                                                                                     NA                                                           ---                                                                
  151                                    33            B                 Follicular cyst                                                                                                       NA                                                           ---                                                                
  156                                    45            B                 Serous cystadenoma                                                                                                    ---                                                          ---                                                                
  157                                    58            B                 Thecofibroma                                                                                                          ---                                                          ---                                                                
  159                                    49            B                 Cystic teratoma                                                                                                       ---                                                          ---                                                                
  176                                    67            B                 Cystic teratoma of the ovary                                                                                          ---                                                          ---                                                                
  179                                    45            B                 Uterus myomatosus                                                                                                     ---                                                          ---                                                                
  180                                    35            B                 Uterus myomatosus                                                                                                     ---                                                          ---                                                                
  182                                    43            B                 CIN III, ovarian cyst, endometriosis                                                                                  NA                                                           ---                                                                
  183                                    35            B                 Ovarian cyst, endometriosis                                                                                           NA                                                           ---                                                                
  185                                    62            B                 Ovarian cyst, cystadenofibroma,                                                                                       ---                                                          ---                                                                
  186                                    36            B                 Teratoma of the ovary                                                                                                 ---                                                          ---                                                                
  187                                    36            B                 Endometriosis                                                                                                         ---                                                          ---                                                                
  188                                    72            B                 Thecofibroma                                                                                                          ---                                                          ---                                                                
  189                                    45            B                 Ovarian cyst                                                                                                          ---                                                          ---                                                                
  191                                    28            B                 Chronical salpingitis, oophoritis                                                                                     ---                                                          ---                                                                
  192                                    52            B                 Thecofibroma                                                                                                          ---                                                          ---                                                                
  141[\*](#TF1-1){ref-type="table-fn"}   60            OC                Low-grade endometrioid adenocarcinoma                                                            IB           G1      ---                                                          ---                                                                No mutation identified in primary tumor
  170[\*](#TF1-1){ref-type="table-fn"}   67            OC                Serous carcinoma                                                                                 IIIA         G1      ---                                                          ---                                                                No mutation identified in primary tumor
  134[\*](#TF1-1){ref-type="table-fn"}   52            OC                Serous                                                                                           IIIC         G3      ---                                                          ---                                                                No mutation identified in primary tumor
  142[\*](#TF1-1){ref-type="table-fn"}   58            OC                Serous                                                                                           IIIC         G2      *TP53* p.Q104[\*](#TF1-1){ref-type="table-fn"}, c.310C\>T    ---                                                                Tubal ligation
  153[\*](#TF1-1){ref-type="table-fn"}   62            OC                Metastatic ovarian cancer from lobular mamma carcinoma                                                                ---                                                          ---                                                                Two or more malignant tumors
  128[\*](#TF1-1){ref-type="table-fn"}   58            BC, OC            Ductal breast cancer, mucinous adenocarcinoma ovary                                              IIIC         G2      ---                                                          ---                                                                Two or more malignant tumors

NOTE. Mutations detected by NGS, safe sequencing system (SafeSeqS), and digital droplet polymerase chain reaction (ddPCR).

Abbreviations: ---, no mutation detected; B, benign disease; BC, breast cancer; CIN, cervical intraepithelial neoplasia; EC, endometrial cancer; FIGO, International Federation of Gynecology and Obstetrics; G, grade; LMP, low malignant potential; NA, not applicable; NGS, next-generation sequencing; OC, ovarian cancer; OC meta, cancer metastasized in ovaries; UC, uterine cancer;

Excluded from final analysis.

Corresponding tumor tissue was available for 21 of the included patients with OC (70%), three patients with EC (60%), 19 patients with benign diseases (70.4%), and the patient with a metastatic signet ring carcinoma. Uterine lavage was performed before surgery for suspected malignant adnexal pathology, immediately after induction of anesthesia. Lavage samples were centrifuged at 300 × *g* for 10 minutes at room temperature. DNA was isolated from the cell pellet (QIAamp MinElute Media Kit, No. 57414; Qiagen, Hilden, Germany), and concentration was determined using a Qubit fluorometer (ThermoFisher, Waltham, MA).

Lavage Technique
----------------

First, an antiseptic lotion was used for cleaning the cervix. Using a bullet forceps, the cervix was grasped at 12 o\'clock. A three-way catheter (Coloplast AH5312; Coloplast, Minneapolis, MN) was inserted into the cervical canal, and the balloon was inflated with approximately 1 mL of saline to seal the cervical canal. If the cervical canal was too narrow to pass the catheter, it was dilated to 4 mm with Hegar dilators. Two 10-mL syringes, one of them containing 10 mL of saline, were connected to two of the catheter tubes. The patient was put into an anti-Trendelenburg position. By pushing on the plunger of the syringe containing saline, the uterine cavity and fallopian tubes were slowly perfused. Simultaneously, the plunger of the empty syringe was gently pulled out. Finally, the balloon was deflated, and the catheter was removed. This procedure was partially still under optimization during sample collection within this proof-of-concept study.

Massively Parallel Sequencing
-----------------------------

Multiplex amplification and sequencing of 136 amplicons covering approximately 13,000 base pairs were applied to lavage samples, and the corresponding tumor specimens were^[@B22]^ modified as described earlier.^[@B23]^ Amplicons comprised gene regions of *AKT1*, *APC*, *BRAF*, *CDKN2A*, *CTNNB1*, *EGFR*, *FBXW7*, *FGFR2*, *KRAS*, *NRAS*, *PIK3CA*, *PIK3R1*, *POLE*, *PPP2R1A*, *PTEN*, and *TP53* (Data Supplement). Confirmation of each detected mutation was carried out through independent singleplex amplification (safe sequencing system \[SafeSeqS\]) and sequencing using the same DNA sample, as described in Bettegowda et al.^[@B23]^

Digital Droplet Polymerase Chain Reaction
-----------------------------------------

Lavage samples of six patients were analyzed by digital droplet polymerase chain reaction (ddPCR; QX100 Droplet Digital PCR System; Bio-Rad Laboratories, Hercules, CA). Mutations previously identified in tumor tissue were evaluated. For confirmation, DNA from tumor tissue was analyzed through ddPCR as well. Custom TaqMan SNP Genotyping Assays (No. 4331349; Life Technologies, Carlsbad, CA) were designed using Primer Express 3.0 software (ThermoFisher). A positive control and wild-type control were included in every polymerase chain reaction run. Ten to 20 ng of template DNA was used per amplification. All samples were analyzed at least in duplicates. To ensure specificity, all designed assays were also tested on samples obtained from three patients with benign diseases.

RESULTS
=======

Identification of Tumor Cells in Lavage Samples
-----------------------------------------------

Sufficient amounts of DNA were obtained from each lavage sample (mean, 1.8 μg; range, 33 ng to 22.9 μg). Lavage samples were classified as positive when one or more mutations were detected in one sample.

Lavage specimens were analyzed by massively parallel sequencing. In patients with malignant diseases, a median mutant allele fraction of 13.9% (range, 1.5% to 44.6%) was detected (Data Supplement). All samples of patients with malignant diseases were analyzed in the manner described in [Figure 1](#F1){ref-type="fig"}.

![Scheme of the procedure applied for mutation analysis of lavage samples from patients with malignant diseases. When a mutation was detected in the lavage specimen by next-generation sequencing (NGS), it was confirmed by safe sequencing system (SafeSeqS) and analysis of the corresponding tumor tissue. If no mutation was detected by NGS, singleplex methods (SafeSeqS for all 12 patients and digital droplet polymerase chain reaction for six patients) were used to detect a specific mutation previously determined in tumor tissue of 12 patients. (\*) Excluded because of previous tubal ligation, germline mutation, or two or more malignant tumors present. MUT, mutation.](zlj9991057100001){#F1}

In case a mutation was detected in lavage specimens, the results were validated twice. First, the index mutation found in the lavage sample (mutation with highest mutant allele fraction) was assessed in an independent singleplex (SafeSeqS) experiment. In all malignant cases with previously identified mutations, the precise mutation was confirmed.

Second, if primary tumor tissue was available, mutation analysis was conducted in the primary sample as well. In all but two patients, the same mutation was identified. For patient 144, a *KRAS* G12C mutation (4.1%) was detected in the lavage fluid only, possibly because of heterogeneity or low tumor cell content of the tissue specimen. For patient 143, a mutation (*TP53* p.L194R) was found that was present in a metastatic lesion but absent in the primary tumor.

When no mutation was found in the lavage DNA, we evaluated the primary tumors by multiplex sequencing, if available. Identified mutations could be verified in the lavage fluids by SafeSeqS (n = 1) or ddPCR (n = 5) with a sensitivity of 0.1% ([Fig 2](#F2){ref-type="fig"}).

![Mutation analysis of lavage specimens by next-generation sequencing (NGS) or singleplex approaches (safe sequencing system \[SafeSeqS\] and digital droplet polymerase chain reaction \[ddPCR\]) depicted as percentage of mutant alleles present. (A) Results obtained from analysis of patients with OC included in final analysis. All samples were analyzed by NGS, 12 initially negative samples were analyzed by SafeSeqS, and six of those were also analyzed by ddPCR. (B) Results obtained from analysis of patients with other malignancies, including low-malignant-potential ovarian tumor, uterine carcinosarcoma, and signet ring carcinoma metastasized to the ovaries, as well as five patients with endometrial carcinoma. Disease type and International Federation of Gynecology and Obstetrics stage of disease, if applicable, are listed on the *y*-axis. ca., carcinoma; Endom., endometrial; potent, potential.](zlj9991057100002){#F2}

Next-generation sequencing (NGS) identified at least one mutation in 18 (60%) of 30 patients with OC. Furthermore, a mutation was also identified in a lavage sample of a patient with a signet ring carcinoma that had spread to the ovaries, a uterine carcinoma, and a tumor with low malignant potential ([Fig 2](#F2){ref-type="fig"}B). When no mutation was found in the lavage DNA (n = 15), we evaluated the available primary tumors by multiplex sequencing (n = 12). Identified mutations were verified in the lavage fluids by SafeSeqS (one of 12 tumors) or ddPCR (five of six tumors) with a sensitivity of 0.1% ([Fig 2](#F2){ref-type="fig"}). Mutation types identified in tumor tissues or lavage samples by either method are listed in [Table 1](#T1){ref-type="table"}.

In total, 24 (80%) of 30 patients with OC were identified by either the NGS approach or singleplex analysis for the presence of a mutation previously identified in the primary tumor tissue. Applying NGS of the same panel of genes, lavage samples of five patients with stage IA EC were analyzed. In all five samples (100%), mutations were identified, with mutant allele frequencies ranging between 3.91% and 46.42% ([Fig 2](#F2){ref-type="fig"}B).

Analysis of a Lavage Sample of a Woman With an Occult OC
--------------------------------------------------------

A lavage sample was analyzed that was taken from a 41-year-old *BRCA1* mutation carrier (patient 205) submitted for RRSO, who was recruited from the prospectively running LUSTIC trial. Although no signs of cancer were present (CA-125 and transvaginal ultrasound were inconspicuous) before surgery, laparoscopy and subsequent laparotomy revealed the presence of a few peritoneal nodules and a 15-mm peritoneal lesion on the right diaphragm as the only other site of metastatic spread. Final histopathology revealed a grade 2, pT3b, pN0, International Federation of Gynecology and Obstetrics stage IIIB serous OC. Both ovaries showed microscopic involvement, and STICs were found in both tubes. *TP53* mutation analysis of the lavage sample was performed by NGS, an approach suitable for screening of a high-risk population. A frameshift mutation (*TP53* p.V217*fs*, c.650delT) was detected and confirmed by ddPCR (16.8%) and SafeSeqS (17.3%) in DNA from the lavage and the corresponding tissue sample (Speiser et al, submitted for publication).

Analysis of Lavage Samples From Patients With Benign Gynecologic Diseases
-------------------------------------------------------------------------

Eight (29.6%) of 27 lavage samples from patients with benign gynecologic diseases were found to be mutated by NGS. In six of these patients, a *KRAS* mutation was detected ([Table 1](#T1){ref-type="table"}). No mutations were identified in 19 tested tissue samples of patients with benign diseases. Other genes affected only one or two patients (*FBXW7*, *PIK3CA*, *PIK3R1*, or *PTEN*), some of whom also harbored *KRAS* gene mutations. None of the lavage samples harbored *TP53* mutations, the gene that was most commonly mutated in the patients with OC ([Fig 3](#F3){ref-type="fig"}).

![Distribution of genes affected by mutations, leading to the identification of different sample types (index mutation). A mutation of the *TP53* gene is the most important marker in identifying ovarian cancer (OC), whereas *KRAS* mutations can also be observed in patients with benign diseases. EC, endometrial cancer.](zlj9991057100003){#F3}

DISCUSSION
==========

This pilot study demonstrates that cells shed from Müllerian duct cancers, including OC and EC, can be collected through a lavage of the uterine cavity, in which tumor-specific mutations can be detected through massively parallel sequencing. Sixty percent of patients with OC had mutations in their lavage samples detected with the NGS approach, a technology possibly suitable for routine application.

In patients with known mutation status of the primary tumor tissue but nondetectable mutation in the lavage by NGS, two methods with an even higher sensitivity were applied (SafeSeqS and ddPCR). Using these methods, mutation detection rates in patients with OC could be increased to 80%, demonstrating the general validity of this concept.

Because we could demonstrate that the lavage of a patient with occult OC was positive for cancer cells, shedding and transtubal transportation of cancer cells seems to take place early in OC propagation. Approximately one third of lavages from patients with benign disease tested positive with the panel of genes applied. In most cases, these were a result of mutations in the *KRAS* gene or other genes not commonly mutated in OC. All lavages of the five patients with EC tested positive for cancer cells using the NGS approach.

New insights into the biology of high-grade serous OC led to the hypothesis that cells of these tumors and possibly even their precursor lesions can be transported into the uterine cavity. Therefore, we established the lavage technique to collect and identify these cells. As opposed to Pap smears, as used in the study by Kinde et al,^[@B22]^ the lavage permits the evaluation of cells closer to the ovaries (ie, in the uterine cavity and the fallopian tubes). The evaluation of lavage fluids resulted in higher sensitivity than previously reported in Pap smear fluids (60% *v* 41%, respectively). We show here that, even in lavage samples, the fraction of mutant alleles can be below the detection limit of the NGS approach and that using individualized, singleplex methods (SafeSeqS or ddPCR) allows detection of such mutations. With the amount of DNA and depth of coverage used, the NGS approach could reliably detect mutations present in more than 1% of the total alleles examined. Only a multiplex assay such as the NGS method used here is applicable for screening of patients with OC as a result of the large number of different mutations in *TP53* that can occur in OC. Therefore, advances in sequencing technologies should be able to increase detection of OC in lavage fluids in the future.

Both the lavage and liquid Pap smear suffer from the fact that few patients with early disease were analyzed because most OCs are not detected until they are advanced. The detection of early disease is one of the most important goals because of the expected greater impact on mortality along with higher chances of surgically curable disease. Still, it is encouraging that two of four stage I OCs were detected in the study by Kinde et al^[@B22]^ and two of two stage I OCs were detected in the current study. Even more promising for early diagnosis is our detection of a clinically occult OC that was missed by the current state-of-the-art diagnostic methods. As a result of transperitoneal spread, serous OC may not progress stage by stage, and earlier detection will not necessarily result in a stage shift. However, earlier detection of serous OC equates to less tumor burden at diagnosis, a substantial increase in patients who can undergo complete tumor resection, and less radical procedures necessary to achieve this result. Among women with an increased risk of HGSC who undergo RRSO, 10% to 15% are diagnosed with an STIC or an invasive neoplasm.^[@B11],[@B24]--[@B31]^ Notably, more than 90% of STICs harbor *TP53* mutations, like the more advanced lesions that evolve from them. Thus, the lavage technology has the potential to not only detect OC earlier, but also detect premalignant lesions. This is further supported by the progression time from STIC to an invasive carcinoma, opening a window for early detection or even prevention of HGSC. Cancers that the lavage procedure missed were International Federation of Gynecology and Obstetrics stage IIIC or IV. However, such a diagnostic method is not needed for advanced stages, and a successful detection of all of these advanced cancers was not expected as a result of physical reasons. A disadvantage of the invasive lavage method may be the theoretical risk of infection, although no such infections have been observed to date (P. Speiser, personal communication, September 2015).

Possible improvements for future follow-up studies comprise performing the lavage at specific time points during the menstrual cycle. Moreover, the lavage procedure is standardized now, and one Conformité Européene (CE)-certified catheter is used, in contrast to the proof-of-concept study, where these issues were still being optimized. Additional information will be obtained from comparing liquid Pap smears with lavage samples from the same patients. Both are expected to be exquisitely specific for neoplasia given the nature of the biomarker assessed (somatic mutations). However, it cannot be excluded that benign tumors, which are also neoplastic, contribute mutations to the analyzed fluids. To address this for the first time, we also analyzed samples of patients with benign diseases. In eight of 27 lavage samples, a mutation was detected. Some of these cases may be explained by the fact that low-grade serous carcinoma, in contrast to HGSC, shows a slow transition from benign to malignant stage and thereby accumulates mutations in *KRAS*, *BRAF*, or *PPP2R1A* and other genes.^[@B32]^ Whether these cases should be considered true-positive results is debatable; a similar debate has been waged for early cervical lesions in conventional Pap smears or small adenomas in colonoscopy. These results, especially the high frequency of *KRAS* mutations, suggest the exclusion of certain genes from mutation analysis for differential diagnosis. The clinically most relevant group is patients with HGSC, which in almost all patients can be detected via *TP53* analysis. In patient 131, besides a predominant *KRAS* mutation, mutations in several other genes were detected, including *TP53* (Data Supplement). Thus, the exclusion of *KRAS* will not alter the test result because of the present *TP53* mutation. We were also able to reproduce the high frequency in EC detection, as published by Kinde et al.^[@B22]^ Although we analyzed lavage samples of only five patients with EC, the potential of the lavage technique is obvious.

In summary, this proof-of-concept study demonstrates the potentially high diagnostic power of the lavage approach for OC and EC detection, especially for early detection in high-risk populations. This is currently being investigated in a large study (ClinicalTrials.gov identifier: NCT02039388).
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